Shattuck Labs, Inc. — fact timeline

Shattuck Labs, Inc. shareholders approved Approval of Amendment and Restatement of the 2020 Equity Incentive Plan.

“Proposal 5. Approval of Amendment and Restatement of the 2020 Equity Incentive Plan 43,498,166 10,709,563 17 10,607,421”

Shattuck Labs, Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation.

“1 Year 2 Years 3 Years Abstentions Broker Non-Votes Proposal 4. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation 53,948,458 21,627 237,643 18 10,607,421”

Shattuck Labs, Inc. shareholders approved Advisory Vote on Executive Compensation.

“Proposal 3. Advisory Vote on Executive Compensation 49,849,887 4,356,199 1,660 10,607,421”

Shattuck Labs, Inc. shareholders approved Ratification of KPMG LLP as Independent Auditor.

“Proposal 2. Ratification of KPMG LLP as Independent Auditor 64,802,807 7,317 5,043 0”

Shattuck Labs, Inc. shareholders approved Election of Class III Director Nominees.

“Proposal 1. Election of Class III Director Nominees • Taylor Schreiber, M.D., Ph.D. 51,347,234 2,860,512 10,607,421 • Helen M. Boudreau 50,110,095 4,097,651 10,607,421 • Clay Siegall, Ph.D. 50,388,129 3,819,617 10,607,421”

Shattuck Labs, Inc. reported first quarter ended March 31, 2026 results: net income $14.8 million for the quarter ended March 31, 2026, or $0.13 per basic and diluted share, EPS $0.13 per basic and diluted share.

“Shattuck Labs Reports First Quarter 2026 Financial Results”

Shattuck Labs, Inc. entered into Sales Agreement with Leerink Partners LLC valued at $75,000,000 (effective 2026-01-22).

“On January 22, 2026, Shattuck Labs, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock, $0.0001 par value per share (the “Shares”), through the Agent. The offering and sale of up to $75,000,000 of the Shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-292697) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on January 13, 2026 and declared effective by the SEC on January 21, 2026, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on January 22, 2026.”

Shattuck Labs, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $18.5 million for the quarter ended March 31, 2024, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share.

“Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended March 31, 2024 and provided recent business highlights.”

Dr. Clay Siegall was appointed as Class III director at Shattuck Labs, Inc..

“On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.”

Dr. Kate Sasser was appointed as Class II director at Shattuck Labs, Inc..

“On March 1, 2024, the Board of Directors (the “Board”) of Shattuck Labs, Inc. (the “Company”) expanded its size and appointed: (i) Dr. Kate Sasser as a Class II director to serve until the Company’s 2025 Annual Meeting of Stockholders and until her successor is duly elected and qualified and (ii) Dr. Clay Siegall as a Class III director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately.”

Shattuck Labs, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent business highlights.”